Scotia Capital’s Bristol-Myers Squibb BMY Stock Holding History

Scotia Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,700	Closed	-$323K	–	699
2015 Q4	$323K	Sell	4,700 -95,300	-95%	-$6.3M	0.01%	664
2015 Q3	$5.92M	Hold	100,000	–	–	0.13%	119
2015 Q2	$6.65M	Buy	+100,000	New	+$6.59M	0.13%	124

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Scotia Capital's BMY Position: Q2 2026 in Review

Scotia Capital reduced its Bristol-Myers Squibb (BMY) stake by 4.5% in Q2 2026, selling an estimated $423K and leaving 156,665 shares worth $9.03M. The position accounts for 0.03% of the portfolio, ranked #238.

Scotia Capital first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $22.3M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Scotia Capital held 156,665 shares of Bristol-Myers Squibb worth $9.03M as of Q2 2026.
Scotia Capital sold 7,361 Bristol-Myers Squibb shares in Q2 2026, an estimated $423K.
Bristol-Myers Squibb made up 0.03% of Scotia Capital's portfolio in Q2 2026, its #238 holding.
Scotia Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
Scotia Capital's Bristol-Myers Squibb position peaked at $22.3M in Q1 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.